Anteris Technologies develops structural heart devices, led by the DurAVR biomimetic transcatheter aortic valve designed to mimic native valve function. The system combines a single-piece tissue valve, ADAPT anti-calcification tissue processing, and a balloon-expandable delivery platform aimed at easier coronary access. The company is clinically focused on aortic valve disease and remains at a development and early commercialization stage relative to large heart-valve incumbents.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0.6 | — | -21.9 | — |
| Q2 2025 | 0.6 | — | -20.8 | — |
| Q3 2025 | 0.4 | — | -22.2 | — |
| Q4 2025 | 0.3 | — | -29.2 | — |
| Q1 2026 | 0.5 | -11.2% | -23 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Power Solutions International, Inc. (PSIX), Canadian Solar Inc. (CSIQ), Lightwave Logic, Inc. (LWLG), American Public Education, Inc. (APEI), Barrett Business Services, Inc. (BBSI), Polestar Automotive Holding UK PLC (PSNYW)